To further validate the antitumor efficacy of L-BTZ in MM treatment, especially in BTZ-resistant scenarios, the OPM-2 xenograft model, another human MM cell line resistant to BTZ compared to NCI-H929, was applied [25]. Here, CASC3 is linked to Miyoshi myopathy.